Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
UTI Medium to Long Duration Fund-Growth - Direct
★★★★★ 3rd-party
External rating
- Source: Third-party data provider (Groww/CRISIL)
- Original rating: 2/5, displayed as-is — TopFund does not modify third-party ratings
- Refresh frequency: Whenever TopFund re-syncs this fund's data
- Limitations: The provider's own rating methodology isn't disclosed here — see the provider's own site for their criteria
TopFund Score: 43/100 · Weak
How this score is calculated
- Star rating (35%)2/5
- 3Y CAGR (30%)6.21%
- Expense ratio (20%)1.32%
- AUM (15%)₹303 Cr
Not investment advice — an analytical read of public fund data. Methodology →
UTI Mutual Fund · Income/Debt Oriented · Medium to Long Term Fund
₹83.41
AUM: ₹303 Cr
NAV updated about 23 hours ago
Plan
Direct
Option
Growth
Risk
Moderate
Expense Ratio
1.32%
Exit Load
Nil
Fund Manager
Amandeep Chopra
Inception
Jan 2013
Benchmark
CRISIL Medium to Long Duration Debt A-III Index
Sharpe Ratio
-1.69
Std Dev (1Y)
2.05%
Historical Returns (CAGR)
Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.
1m
+0.61%
3m
-0.23%
6m
+2.76%
1y
+2.89%
3y
+6.21%
5y
+6.91%
10y
+5.03%
since inception
+6.64%
TopFund's Take on UTI Medium to Long Duration Fund-Growth - Direct
UTI Medium to Long Duration Fund-Growth - Direct lags behind most of its peers in the Medium to Long Term Fund category, currently carrying a 2-star rating. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 43/100.
Cost: At 1.32%, the expense ratio runs 140% above the Medium to Long Term Fund category average of 0.55%. That gap is worth weighing against the fund's actual performance versus cheaper peers before committing to a long SIP.
Risk-adjusted performance: Over the trailing 1-year period, the fund shows a negative Sharpe ratio of -1.69 — over the past year, returns haven't kept pace with the volatility involved, even before accounting for the risk-free rate. Separately, annualised volatility of 2.05% is on the lower side for a Medium to Long Term Fund fund, suggesting a comparatively smoother ride.
Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Income/Debt Oriented fund.
This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.
Sector Allocation
Asset Allocation
Fund Snapshot
Tools & Guides for This Fund
Frequently Asked Questions about UTI Medium to Long Duration Fund-Growth - Direct
The current NAV (Net Asset Value) of UTI Medium to Long Duration Fund-Growth - Direct is ₹83.41. NAV is updated every business day after market close by AMFI.
1Y: 2.89% · 3Y CAGR: 6.21% · 5Y CAGR: 6.91%
The expense ratio of UTI Medium to Long Duration Fund-Growth - Direct is 1.32% per annum. This is the annual fee charged by the fund to manage your investment.
UTI Medium to Long Duration Fund-Growth - Direct is managed by Amandeep Chopra at UTI Mutual Fund.
UTI Medium to Long Duration Fund-Growth - Direct is classified as a Moderate risk fund. It is suitable for investors with a moderate risk appetite.
UTI Medium to Long Duration Fund-Growth - Direct is a Medium to Long Term Fund fund. SIP suitability depends on your investment goal and risk profile.
You can start a SIP in UTI Medium to Long Duration Fund-Growth - Direct with as little as ₹500 per month through most mutual fund platforms. The minimum lump sum investment is typically ₹1,000.
The Assets Under Management (AUM) of UTI Medium to Long Duration Fund-Growth - Direct is ₹303 crore. AUM indicates the total market value of assets managed by the fund.
* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.
Discussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.